Change Language

Select Language

Press Release:

Global Hospital Acquired Disease Testing Market to Reach US$ 2,190 Million by 2024, Modernization of Healthcare Infrastructure Impelling Growth

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Global Hospital Acquired Disease Market Overview 2021-2026:

The global hospital acquired disease testing market reached a value of US$ 7.32 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 18.5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Hospital acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and the emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Another reason can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patients’ own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

 

 
 

www.imarcgroup.com

Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information on the regional analysis of this market, Request Sample

Market Trends:

The market for hospital acquired disease testing is currently exhibiting double digit growth rates. Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market. 

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital acquired disease testing market report, along with forecasts for growth at the global and regional level from 2021-2026. Our report has categorized the market based on indication.

Breakup by Indication:

  • UTI (Urinary Tract Infection)
  • SSI (Surgical Site Infection)
  • Pneumonia
  • Bloodstream Infections
  • MRSA (Methicillin-Resistant Staphylococcus Aureus)
  • Others
     

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.

Regional Insights:

 

 
 

www.imarcgroup.com

To get more information on the regional analysis of this market, Request Sample

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America
     

Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Competitive Landscape:

The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.

This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.
 

Report Coverage:

Report Features Details
Base Year of the Analysis 2020
Historical Period 2015-2020
Forecast Period 2021-2026
Units US$ Billion
Segment Coverage Indication, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Companies Covered Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License $ 2299
Five User License $ 3399
Corporate License $ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

1    Preface
2    Scope and Methodology
    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction
    4.1    Overview
    4.2    Key Industry Trends
5    Global Hospital Acquired Disease Testing Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Breakup by Indication
    5.5    Market Breakup by Region
    5.6    Market Forecast
    5.7    SWOT Analysis
        5.7.1    Overview
        5.7.2    Strengths
        5.7.3    Weaknesses
        5.7.4    Opportunities
        5.7.5    Threats
    5.8    Value Chain Analysis
    5.9    Porters Five Forces Analysis
        5.9.1    Overview
        5.9.2    Bargaining Power of Buyers
        5.9.3    Bargaining Power of Suppliers
        5.9.4    Degree of Competition
        5.9.5    Threat of New Entrants
        5.9.6    Threat of Substitutes
    5.10    Price Analysis
6    Market Breakup by Indication
    6.1    UTI (Urinary Tract Infection)
        6.1.1    Market Trends
        6.1.2    Market Forecast
    6.2    SSI (Surgical Site Infection)
        6.2.1    Market Trends
        6.2.2    Market Forecast
    6.3    Pneumonia
        6.3.1    Market Trends
        6.3.2    Market Forecast
    6.4    Bloodstream Infections
        6.4.1    Market Trends
        6.4.2    Market Forecast
    6.5    MRSA (Methicillin-Resistant Staphylococcus Aureus)
        6.5.1    Market Trends
        6.5.2    Market Forecast
    6.6    Others
        6.6.1    Market Trends
        6.6.2    Market Forecast
7    Market Breakup by Region
    7.1    North America
        7.1.1    Market Trends
        7.1.2    Market Forecast
    7.2    Europe
        7.2.1    Market Trends
        7.2.2    Market Forecast
    7.3    Asia Pacific
        7.3.1    Market Trends
        7.3.2    Market Forecast
    7.4    Middle East and Africa
        7.4.1    Market Trends
        7.4.2    Market Forecast
    7.5    Latin America
        7.5.1    Market Trends
        7.5.2    Market Forecast
8    Competitive Landscape
    8.1    Market Structure
    8.2    Key Players
    8.3    Profiles of Key Players
        8.3.1    Abbott Laboratories
        8.3.2    Alere, Inc.
        8.3.3    Becton, Dickinson and Company
        8.3.4    bioMérieux SA
        8.3.5    F. Hoffmann-La Roche Ltd.
        8.3.6    Hologic, Inc.
        8.3.7    QIAGEN
        8.3.8    Siemens Healthcare
        8.3.9    Diatherix Laboratories, Inc.
        8.3.10    Meridian Bioscience, Inc.
        8.3.11    Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
        8.3.12    Cepheid, Inc.

List of Figures

Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2020
Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2020
Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
Figure 7: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million US$), 2015 & 2020
Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million US$), 2015 & 2020
Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million US$), 2015 & 2020
Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million US$), 2015 & 2020
Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million US$), 2015 & 2020
Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million US$), 2015 & 2020
Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026

List of Tables

Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2021-2026
Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
Table 5: Global: Hospital Acquired Disease Testing Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Key Questions Answered in This Report

The global hospital acquired disease testing market size was valued at US$ 7.32 Billion in 2020.

According to the estimates by IMARC Group, the global hospital acquired disease testing market is expected to exhibit strong growth during 2021-2026. 

Rising incidences of HAIs upon exposure to infected patients, contaminated linens, medical equipment, etc., are currently driving the market for hospital acquired disease testing.

Several technological advancements have led to the introduction of microarrays, solid phase hybridization, polymerase chain reaction (PCR) and real-time location systems (RTLSs) for detecting and monitoring HAIs, thereby representing the one of the key trends in the global hospital acquired disease testing market.

Sudden outbreak of the COVID-19 pandemic has led to the rising demand for advanced and effective testing devices for hospital acquired diseases based on the increasing risk of coronavirus contraction upon hospital visits.

On the basis of the indication, the market has been bifurcated into urinary tract infection, surgical site infection (SSI), pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus (MRSA), and others. Amongst these, urinary tract infection (UTI) holds the majority of the total market share.

Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.

The key companies in the global hospital acquired disease testing market are Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Related Report

Clinical Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Read More

Clinical Nutrition Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Read More

Local Anesthesia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Read More

Long Term Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Read More

Plasma Fractionation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Read More

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )

Drop us an email at

sales@imarcgroup.com

Social Links